Theravance Biopharma (TBPH) Other financing activities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Other financing activities data on file, last reported at $241000.0 in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $241000.0 in Q1 2026; TTM through Mar 2026 was $862000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $766000.0, up 50.79% from the prior year.
• Other financing activities for Q1 2026 stood at $241000.0, down from $488000.0 in the prior quarter.
• Over the last five years, Other financing activities for TBPH reached as high as $21.0 million in Q4 2022 and fell as low as -$20.7 million in Q3 2022.
• Historically, Other financing activities has averaged $192714.3 across 5 years, with a median of $173000.0 in 2023.
• On a YoY basis, Other financing activities climbed as much as 3375.33% in 2022 and fell as far as 823.7% in 2022.
• Year by year, Other financing activities stood at $21.0 million in 2022, then sank by 99.18% to $173000.0 in 2023, then slipped by 23.12% to $133000.0 in 2024, then surged by 266.92% to $488000.0 in 2025, then tumbled by 50.61% to $241000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $241000.0 in Q1 2026, $488000.0 in Q4 2025, and $133000.0 in Q4 2024.